The expression of PD-1 and PD-L1 has drawn great attention to the impact of lymphoma treatment, particularly in aggressive lymphomas such as DLBCL, NOS, where they evade immune response and drive aggressiveness.21 Identification of patients for PD-1/PD-L1 immunotherapy, possibly through IHC evaluation, holds promise for better patient outcomes and further research in checkpoint inhibitor treatment. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.